⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21165829 | 0.81 | ACHE (0.36) | — | |
| SCHEMBL15182435 | 0.79 | CTSA (0.30) | — | |
| SCHEMBL25978877 | 0.79 | — | — | |
| SCHEMBL16562635 | 0.72 | — | — | |
| SCHEMBL10597368 | 0.72 | FDPS (0.32) | — | |
| SCHEMBL410611 | 0.69 | — | — | |
| SCHEMBL11871312 | 0.69 | — | — | |
| SCHEMBL24227037 | 0.68 | — | — | |
| SCHEMBL24317079 | 0.68 | FDPS (0.30) | — | |
| SCHEMBL16904641 | 0.67 | CHRNB2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400168-A2 | ANTISENSE NUCLEIC ACIDS | Nippon Shinyaku Co., Ltd. (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024112809-A2 | CELL-PENETRATING PEPTIDES, CONJUGATES THEREOF, AND METHODS OF THEIR USE | PEPGEN INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2023178230-A1 | PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER CONJUGATES | SAREPTA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023171804-A1 | ANTIVIRAL ANTISENSE OLIGOMER | 日本新薬株式会社 | 2023-09-14 | — | — | WO | disclosed |
| EP-4219717-A2 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4122497-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4112083-A1 | ANTISENSE NUCLEIC ACID INDUCING SKIPPING OF EXON 51 | Nippon Shinyaku Co., Ltd. (JP) | 2023-01-04 | — | — | EP | disclosed |
| EP-4083208-A1 | ANTISENSE NUCLEIC ACID THAT INDUCES SKIPPING OF EXON 50 | Nippon Shinyaku Co., Ltd. (JP) | 2022-11-02 | — | — | EP | disclosed |
| WO-2022192749-A2 | METHODS OF TREATING DUCHENNE MUSCULAR DYSTROPHY USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES | PEPGEN INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022140535-A1 | COMPOSITIONS COMPRISING EXON SKIPPING OLIGONUCLEOTIDE CONJUGATES FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-9512424-B2 | Antisense nucleic acids | NIPPON SHINYAKU CO., LTD. (JP) | 2016-12-06 | — | — | US | disclosed |
| EP-3018211-A1 | ANTISENSE NUCLEIC ACIDS | Nippon Shinyaku Co., Ltd. (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2612917-B1 | ANTISENSE NUCLEIC ACID | NIPPON SHINYAKU CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20150197534-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | SAREPTA THERAPEUTICS, INC. | 2015-07-16 | — | — | US | disclosed |
| US-9079934-B2 | Antisense nucleic acids | NIPPON SHINYAKU CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20150166995-A1 | ANTISENSE NUCLEIC ACIDS | NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20140343266-A1 | ANTISENSE NUCLEIC ACIDS | NIPPON SHINYAKU CO., LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20130211062-A1 | ANTISENSE NUCLEIC ACIDS | NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2013-08-15 | — | — | US | disclosed |
| EP-2612917-A1 | ANTISENSE NUCLEIC ACID | Nippon Shinyaku Co., Ltd. (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2013100190-A1 | ANTISENSE NUCLEIC ACID | 日本新薬株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |